Single cell transcriptomics of human psoriasis and epidermal specific Ube2l3 deficient mice highlight CXCL16/CXCR6 involvement in psoriasis development.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 41083457.
- Also identified by DOI 10.1038/s41467-025-64106-6 and PMC identifier 12518510.
- Licence recorded as CC BY-NC-ND.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Psoriasis is a chronic, complex immune-mediated inflammatory disorder with cutaneous and systemic manifestations in which keratinocytes, dendritic cells and T cells have central roles. UBE2L3 may be a protective biomarker that regulates the pathogenesis of psoriasis. Here, we identify the IL-17A signaling similarity between human psoriatic skin and Ube2l3 conditional knockout mouse skin in the epidermis rather than dermis. IL-17A is regulated by CXCR6<sup>+</sup> Vγ2<sup>+</sup> γδT cells in mouse while CXCR6<sup>+</sup> CD8<sup>+</sup> T cells in human. CXCL16 is the only chemokine that binds to and stimulates CXCR6. Ube2l3 reduction in keratinocytes activates IL-1β and then promotes CXCL16 expression through STAT3 signaling. Up-regulated CXCL16 in keratinocytes and cDC2/mDC then attracts Vγ2<sup>+</sup> γδT17 or CD8<sup>+</sup> T cells to secrete IL-17A and form a positive feedback loop in keratinocytes supporting psoriatic lesions. Thus, UBE2L3 is a keratinocyte-intrinsic suppressor of epidermal IL-17 production in Vγ2<sup>+</sup> γδT cells in mouse and CD8<sup>+</sup> T cells in human through the CXCL16/CXCR6 signaling pathway in psoriasis.
Medical subject headings
- Psoriasis
- Receptors, CXCR6
- Epidermis
- Chemokine CXCL16
- Ubiquitin-Conjugating Enzymes
- Transcriptome